Sponsors
The bill reduces early direct‑to‑consumer promotion of newly approved drugs to limit misleading marketing and premature uptake, trading improved early safety protections and information quality for reduced patient awareness, possible delays in access, and economic and administrative costs for sponsors and regulators.
Patients (including people with chronic conditions and Medicare/Medicaid beneficiaries) will face fewer early commercial promotions for newly approved drugs during the first 3 years, reducing premature uptake and pressure on clinicians and insurers to adopt treatments before stronger post‑approval safety and effectiveness evidence is available.
Patients and the public (including users on social media and tech workers who moderate content) will encounter less misleading or incomplete promotional information about newly approved drugs during the initial evidence‑gathering period, which can improve the information environment around treatment choices.
Patients (including those with chronic conditions and Medicare/Medicaid beneficiaries) may be less aware of newly approved drugs for up to 3 years, potentially delaying access to beneficial therapies and slowing uptake.
Patients who want direct information about treatment options could have reduced autonomy because limiting direct‑to‑consumer promotion may discourage patient‑driven conversations with clinicians about newly approved therapies.
Drug sponsors and related advertising/media businesses (including smaller firms) will lose an early marketing window, which can reduce revenue and shift costs to other outreach methods.
Based on analysis of 2 sections of legislative text.
Bans direct-to-consumer advertising for newly approved prescription drugs for three years after approval, with a limited third-year waiver and later prohibitions if safety concerns arise.
Introduced February 7, 2025 by Rosa L. Delauro · Last progress February 7, 2025
Bans direct-to-consumer (DTC) advertising — including on social media — for prescription drugs during the first three years after FDA approval, with a limited, reviewable waiver available during the third year if advertising would have an affirmative public health value. After the initial three-year period, the Health and Human Services Secretary may prohibit DTC advertising for a drug if post-approval evidence shows significant adverse health effects. The FDA must revise its drug-advertising regulations within one year of enactment. The new rules apply only to drugs approved on or after the date one year before enactment.